Want to see DMRA full AI Analyst Report?
Damora Therapeutics (DMRA) Income Statement
Damora Therapeutics Income Statement
Last quarter (Q2 2026), Damora Therapeutics's total revenue was $0.00. In Q2, Damora Therapeutics's net income was $-31.17M. See Damora Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ -181.00K | $ -830.00K | $ -490.00K | $ -441.00K | |
| $ 210.87M | $ 16.72M | $ 35.63M | $ 60.72M | $ 51.79M | |
| Depreciation and Amortization | $ 34.00K | $ 181.00K | $ 830.00K | $ 490.00K | $ 441.00K |
| $ -209.75M | $ -21.22M | $ -37.52M | $ -61.13M | $ -51.31M | |
| $ -210.87M | $ -16.90M | $ -36.46M | $ -61.21M | $ -52.23M | |
| $ 1.08M | $ -4.50M | $ -1.89M | $ -417.00K | $ 475.00K | |
| $ -209.79M | $ -21.40M | $ -38.35M | $ -61.62M | $ -51.75M | |
| $ -209.84M | $ -21.44M | $ -38.35M | $ -61.62M | $ -51.75M | |
| Per Share Metrics | |||||
| Basic EPS | $ -152.99 | $ -18.53 | $ -36.08 | $ -60.63 | $ -51.22 |
| Diluted EPS | $ -152.99 | $ -18.53 | $ -36.08 | $ -60.63 | $ -51.22 |
| Weighted Average Shares Outstanding | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M |
| Weighted Average Shares Outstanding (Diluted) | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M |
Currency in USD
